iBio
IBIO
83 hedge funds and large institutions have $65.3M invested in iBio in 2021 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 18 increasing their positions, 30 reducing their positions, and 22 closing their positions.
0% less ownership
Funds ownership: 0.04% → 0.04% (-0%)
4% less capital invested
Capital invested by funds: $68.4M → $65.3M (-$3.04M)
9% less funds holding
Funds holding: 91 → 83 (-8)
36% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 22
40% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 30
42% less call options, than puts
Call options by funds: $2.13M | Put options by funds: $3.67M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$1.33M |
| 2 |
Squarepoint
New York
|
+$706K |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$522K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$324K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$249K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Principal Financial Group
Des Moines,
Iowa
|
-$1.5M |
| 2 |
JP Morgan Chase
New York
|
-$590K |
| 3 |
California Public Employees Retirement System
Sacramento,
California
|
-$561K |
| 4 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$386K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$329K |
IBIO Hedge Fund Activity: Q2 2021 in Review
83 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in iBio (IBIO) for Q2 2021, worth a combined $65.3M — down 4.4% from $68.4M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of IBIO and 14 opened new positions — a net loss of 8 holders — while 30 trimmed existing stakes and 18 added.
The largest buyer was State Street, adding an estimated $1.33M. The largest seller was Principal Financial Group, cutting an estimated $1.5M.
- 83 institutional investors held iBio (IBIO) as of Q2 2021, down from 91 in Q1 2021.
- Funds reported $65.3M of iBio stock for Q2 2021, down 4.4% quarter-over-quarter.
- 14 funds opened new iBio positions in Q2 2021 and 22 closed out, a net change of -8 holders.
- The largest iBio buyer in Q2 2021 was State Street, an estimated $1.33M added.
- The largest iBio seller in Q2 2021 was Principal Financial Group, an estimated $1.5M sold.
Based on aggregated 13F filings for Q2 2021.